PSNLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Personalis, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$15.88+0.23 (+1.47%)
Close on Oct 19, 2026
- Market cap
- $1.67B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$6.75 (+73.93%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Personalis, Inc. saw revenue fall 13.3% to $69.67M over the twelve months to Jun 30, 2026. Free cash flow was -$100.98M.
Revenue
$69.67M
-13.3% vs. a year earlier
Operating income
-$114.31M
TTM Q2 2026
Free cash flow
-$100.98M
TTM Q2 2026
EPS, diluted
-$1.09
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.67B
- P/E ratio
- –
- Price to sales
- 24.03
- Price to book
- 7.12
- Dividend yield
- –
- Free cash flow yield
- -6.03%
Fundamentals
- Revenue
- $69.67M
- Net income
- -$107.18M
- EPS, diluted
- -$1.09
- Free cash flow
- -$100.98M
- Book value per share
- $2.23
- Diluted shares
- 105M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
$69.67M-13.3% YoY
Gross profit
$8.84M-65.0% YoY
Operating income
-$114.31M
Net income
-$107.18M
EPS, diluted
-$1.09
Free cash flow
-$100.98M
Reported periodTrailing twelve months